Sam  Eldessouky net worth and biography

Sam Eldessouky Biography and Net Worth

Sam Eldessouky is responsible for overseeing all of the company’s finance functions, including controllership, tax, treasury and financial planning and analysis, as well as IT.

Prior to Bausch + Lomb, Mr. Eldessouky was the Executive Vice President and Chief Financial Officer of Bausch Health from 2021 to 2022 and Controller and Chief Accounting Officer from 2016 to 2021.

Previously, Mr. Eldessouky served as Senior Vice President, Controller and Chief Accounting Officer for Tyco International plc. During his tenure at Tyco, he played a significant role in the wholesale turnaround of Tyco's business. He also played a key role in executing the spinoffs of Covidien and Tyco Electronics in 2006 and ADT NA and Flow Control in 2012. Prior to that, Mr. Eldessouky spent 10 years at PricewaterhouseCoopers (PwC), where he held several roles of increasing responsibility and served in PwC's National Office, providing technical accounting guidance on complex accounting matters.

Mr. Eldessouky has a Bachelor of Science in Accountancy from Ain Shams University and a Master's degree in Accounting and Finance from the University of Liverpool. He is a Certified Public Accountant and Chartered Global Management Accountant. He served as a member of the Board of Trustees of Financial Executives Research Foundation and Financial Executives International. Additionally, he served as a member of the Global Preparers Forum, an external advisory body to the International Accounting Standards Board, from 2007 to 2013.

What is Sam Eldessouky's net worth?

The estimated net worth of Sam Eldessouky is at least $7.05 million as of March 6th, 2026. Eldessouky owns 403,130 shares of Bausch + Lomb stock worth more than $7,048,325 as of March 12th. This net worth evaluation does not reflect any other assets that Eldessouky may own. Learn More about Sam Eldessouky's net worth.

How do I contact Sam Eldessouky?

The corporate mailing address for Eldessouky and other Bausch + Lomb executives is , , . Bausch + Lomb can also be reached via phone at 905-695-7700. Learn More on Sam Eldessouky's contact information.

Has Sam Eldessouky been buying or selling shares of Bausch + Lomb?

During the last quarter, Sam Eldessouky has bought $68,520.00 in shares of Bausch + Lomb stock. Most recently, on Friday, March 6th, Sam Eldessouky bought 4,000 shares of Bausch + Lomb stock. The stock was acquired at an average cost of $17.13 per share, with a total value of $68,520.00. Following the completion of the transaction, the chief financial officer now directly owns 403,130 shares of the company's stock, valued at $6,905,616.90. Learn More on Sam Eldessouky's trading history.

Who are Bausch + Lomb's active insiders?

Bausch + Lomb's insider roster includes Robert Bailey (EVP), Sam Eldessouky (CFO), and Brent Saunders (CEO). Learn More on Bausch + Lomb's active insiders.

Are insiders buying or selling shares of Bausch + Lomb?

In the last twelve months, Bausch + Lomb insiders bought shares 4 times. They purchased a total of 55,300 shares worth more than $819,028.00. The most recent insider tranaction occured on March, 6th when EVP A Robert D Bailey bought 14,600 shares worth more than $250,390.00. Insiders at Bausch + Lomb own 0.8% of the company. Learn More about insider trades at Bausch + Lomb.

Information on this page was last updated on 3/6/2026.

Sam Eldessouky Insider Trading History at Bausch + Lomb

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2026Buy4,000$17.13$68,520.00403,130View SEC Filing Icon  
See Full Table

Sam Eldessouky Buying and Selling Activity at Bausch + Lomb

This chart shows Sam Eldessouky's buying and selling at Bausch + Lomb by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bausch + Lomb Company Overview

Bausch + Lomb logo
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
Read More

Today's Range

Now: $16.84
Low: $16.66
High: $17.28

50 Day Range

MA: $17.29
Low: $16.20
High: $18.58

2 Week Range

Now: $16.84
Low: $10.45
High: $18.92

Volume

101,563 shs

Average Volume

393,922 shs

Market Capitalization

$5.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58